Qyuns Therapeutics Co (HKSE:02509) Interest Expense: HK$-21 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02509 Qyuns Therapeutics Co Ltd HKSE:02509
9 GF Score
Price HK$16.66
! 5 Warning Signs
View Full Analysis

What is Qyuns Therapeutics Co Interest Expense?

Qyuns Therapeutics Co HKSE:02509 -2.00% 9 Interest Expense is HK$-21 Mil as of Jun. 2026. GuruFocus rates HKSE:02509 with a GF Score™ of 9/100. The stock has 5 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Qyuns Therapeutics Co's interest expense for the six months ended in Jun. 2026 was HK$ -11 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2026 was HK$-21 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Qyuns Therapeutics Co's Operating Income for the six months ended in Jun. 2026 was HK$ 268 Mil. Qyuns Therapeutics Co's Interest Expense for the six months ended in Jun. 2026 was HK$ -11 Mil. Qyuns Therapeutics Co's Interest Coverage for the quarter that ended in Jun. 2026 was 24.35. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Qyuns Therapeutics Co  (HKSE:02509) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Qyuns Therapeutics Co's Interest Expense for the six months ended in Jun. 2026 was HK$-11 Mil. Its Operating Income for the six months ended in Jun. 2026 was HK$268 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2026 was HK$546 Mil.

Qyuns Therapeutics Co's Interest Coverage for the quarter that ended in Jun. 2026 is calculated as

Interest Coverage=-1* Operating Income (Q: Jun. 2026 )/Interest Expense (Q: Jun. 2026 )
=-1*267.956/-11.006
=24.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Qyuns Therapeutics Co Interest Expense Historical Data

* Premium members only.

The historical data trend for Qyuns Therapeutics Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qyuns Therapeutics Co Interest Expense Chart

Qyuns Therapeutics Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
-21.85 -20.87 -18.40 -24.97 -21.24

Qyuns Therapeutics Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Interest Expense Get a 7-Day Free Trial Premium Member Only -15.01 -10.09 -11.52 -9.60 -11.01
HKSE:02509
9GF Score
Qyuns Therapeutics Co Ltd HKSE:02509
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Qyuns Therapeutics Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of HK$-21 Mil mean?
Qyuns Therapeutics Co (HKSE:02509) has a Interest Expense of HK$-21 Mil as of Jun. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Qyuns Therapeutics Co and its competitors.
Is Qyuns Therapeutics Co's Interest Expense too high?
Qyuns Therapeutics Co's current Interest Expense is HK$-21 Mil. Overall, Qyuns Therapeutics Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Qyuns Therapeutics Co's Interest Expense compare to VRTX and REGN?
Qyuns Therapeutics Co's Interest Expense of HK$-21 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Qyuns Therapeutics Co and its competitors. Qyuns Therapeutics Co's current Interest Expense is HK$-21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qyuns Therapeutics Co stock overvalued right now?
Qyuns Therapeutics Co (HKSE:02509) has a current Interest Expense of HK$-21 Mil. The current Interest Expense is HK$-21 Mil. Qyuns Therapeutics Co's overall GF Score™ is 9/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Qyuns Therapeutics Co (HKSE:02509), the current Interest Expense is HK$-21 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Qyuns Therapeutics Co Business Description

Address No. 907 Yaocheng Avenue, Room 1310, Building 1, Taizhou, Jiangsu, CHN
Qyuns Therapeutics Co Ltd is a clinical-stage biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline. It has built a pipeline that covers the four disease areas in the field, including skin, rheumatic, respiratory, and digestive diseases. The group is principally engaged in the research and development, manufacturing, and commercialisation of biologic therapies for autoimmune and allergic diseases. Key revenue is generated from the PRC.
9GF Score

Get the complete analysis for HKSE:02509

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$16.66
Price